New trial data indicates that Tegoprubart, a CD40L-selective humanized monoclonal antibody, may help protect transplanted islet cells while avoiding the toxicities of calcineurin inhibitor–based immunosuppression. In an investigator-initiated study of…
Five-year follow-up data from the RENOVATE-COMPLEX-PCI trial show that intravascular imaging–guided percutaneous coronary intervention leads to better clinical outcomes in patients with complex coronary lesions. Earlier results (median follow-up 2.1…
A bill introduced in the Maryland legislature would require drugmakers to disclose ties to disease awareness campaigns.
New Delhi: The Drugs Technical Advisory Board (DTAB), in its 93rd meeting, has recommended key regulatory changes concerning emergency contraceptive pills, including their inclusion under Schedule K of the Drugs…
New Delhi: Zydus Lifesciences' wholly owned subsidiary Sentynl Therapeutics has entered into an agreement with Korea-based PRG S&T to license an investigational molecule, Progerinin (SLC-D011), for the treatment of Hutchinson-Gilford…
New Delhi: GlaxoSmithKline (GSK) Pharmaceuticals Limited has announced the resignation of its Whole-time Director and Chief Financial Officer, Juby Chandy, following his appointment as Finance Head for the Asia Pacific…
Hyderabad: Ten employees sustained injuries after a pharmaceutical company's bus overturned in Miyapur on the city's outskirts, triggering an immediate response from emergency services.The incident took place when the staff…
New Delhi: CureBay, a hybrid healthcare company focused on expanding access to quality care across underserved communities, has acquired the pharmacy distribution business of Saveo Healthtech.CureBay is backed by Bertelsmann…
A Huntington's researcher treads lightly into the UniQure-FDA fray, J&J wins approval for a first-of-its kind psoriasis pill, and more in today's Readout newsletter.
Philadelphia: The ​U.S. Federal Trade Commission is on the lookout for anticompetitive practices in the pharmaceutical industry with a number of blockbuster drugs near the end of their patents, the…